Sarepta Therapeutics (SRPT) Reiterated Overweight at Morgan Stanley Ahead of a Likely Positive Catalyst
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $182.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
